NCT06045156

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 1,084 (estimated)
• Sponsor: The First Hospital of Jilin University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT

Detailed description

Nearly half of acute ischemic stroke patients underwent intravenous thrombolysis (IVT) failed to achieve excellent functional outcome. Some studies reported that early administrated tirofiban, a selective glycoproteinⅡb/Ⅲa receptor inhibitor, may greatly improve the outcome of patients who received IVT, however they only recruited small sample size. Thus, the investigators design early tirofiban administration after intravenous thrombolysis in acute ischemic stroke (ADVENT) trial, aiming to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT.

Conditions

• Acute Ischemic Stroke

Interventions

Type	Name	Description
DRUG	Tirofiban	Tirofiban is a selective glycoproteinⅡb/Ⅲa receptor inhibitor, which inhibits platelet aggregation and thrombi formation
DRUG	Tirofiban simulant	Tirofiban simulant is placebo packed the same style as tirofiban

Timeline

• Start date: 2024-04-29
• Primary completion: 2026-01-30
• Completion: 2026-12-30
• First posted: 2023-09-21
• Last updated: 2025-12-30

Locations

1 site across 1 country: China